Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Biochim Biophys Acta. 2011 Jan 22;1808(4):1170–1178. doi: 10.1016/j.bbamem.2011.01.012

Structural and functional role of small group-conserved amino acids present on helix-H7 in the β2-adrenergic receptor

Makoto Arakawa ‡,¥, Raja Chakraborty , Jasbir Upadhyaya , Markus Eilers , Philip J Reeves , Steven O Smith ⊥,*, Prashen Chelikani ‡,*
PMCID: PMC3062665  NIHMSID: NIHMS268461  PMID: 21262196

Abstract

Sequence analysis of the class A G protein-coupled receptors (GPCRs) reveals that most of the highly conserved sites are located in the transmembrane helices. A second level of conservation exists involving those residues that are conserved as a group characterized by small and/or weakly polar side chains (Ala, Gly, Ser, Cys, Thr). These positions can have group conservation levels of up to 99% across the class A GPCRs and have been implicated in mediating helix-helix interactions in membrane proteins. We have previously shown that mutation of group-conserved residues present on transmembrane helices H2 – H4 in the β2-adrenergic receptor (β2-AR) can influence both receptor expression and function. We now target the group-conserved sites, Gly3157.42 and Ser3197.46, on H7 for structure-function analysis. Replacing Ser3197.46 with smaller amino acids (Ala or Gly) did not influence the ability of the mutant receptors to bind to the antagonist dihydroalprenolol (DHA) but resulted in ~15–20% agonist-independent activity. Replacement of Ser3197.46 with the larger amino acid leucine lowered the expression of the S319L mutant and its ability to bind DHA. Both the G315A and G315S mutants also exhibited agonist-independent signaling, while the G315L mutant did not show specific binding to DHA. These data indicate that Gly3157.42 and Ser3197.46 are stabilizing β2-AR in an inactive conformation. We discuss our results in the context of van der Waals interactions of Gly3157.42 with Trp2866.48 and hydrogen bonding interactions of Ser3197.46 with amino acids on H1-H2-H7 and with structural water.

Keywords: G-protein coupled receptors (GPCRs), helix packing, beta2-adrenergic receptor, GPCR activation, site-directed mutagenesis

1. INTRODUCTION

G protein-coupled receptors (GPCRs) share a seven transmembrane (TM) helix architecture and activate cognate G-proteins in response to agonist binding. The most extensively studied ligand-activated GPCR is the β2-adrenoreceptor (β2-AR), which mediates physiological responses to epinephrine and norepinephrine. The β2-AR was the first ligand-activated GPCR to be cloned [1], and the first whose crystal structure was determined at high resolution [2]. The crystal structure of β2-AR was solved with the inverse-agonist carazolol bound and provided a direct comparison with the crystal structure of the dark, inactive state of rhodopsin, the dim-light photoreceptor [3, 4]. The two structures revealed the positions of amino acids that are conserved across the family of class A GPCRs, but have left largely unanswered questions concerning their contribution to stabilizing the structure of the inactive receptor or guiding the transition to an active receptor conformation.

Figure 1 presents a two-dimensional representation of the β2-AR sequence with the conserved amino acids highlighted by different colors. There are at least three levels of conservation that can be considered in understanding the structure and function of a given receptor or subfamily of receptors within the GPCR superfamily. The most important set of conserved residues in the class A GPCR family are the “signature” amino acids with sequence identities of >70%. There are 15 signature residues in the transmembrane helices (H1–H7) including the highly conserved (E/D)RY motif on H3 and NPxxY motif on H7.

Figure 1.

Figure 1

Two-dimensional representation of the β2-AR sequence showing amino acid conservation at the three different levels. The receptor has seven transmembrane helices (H1–H7) and a short amphipathic helix (H8) that lies on the cytoplasmic surface of the membrane. Amino acids are shown in single-letter codes. Red circles denote signature-conserved residues that include the (E/D)RY and NPxxY motifs, an asparagine (Asn511.50) on H1, aspartic acid on H2 (Asp792.50), three prolines on helices H5 (Pro2115.50), H6 (Pro2886.50) and H7 (Pro3237.50) and several hydrophobic residues (Leu752.46,Trp1584.50). Blue circles represent small and weakly polar group–conserved residues in the Class A GPCRs excluding the olfactory subfamily, and green circles subfamily-specific residues. The residues in gray are between 70% and 90% conserved in the visual receptor subfamily. CL, cytoplasmic loop; CT, C terminus; EL, extracellular loop; NT, N terminus.

The second level of conservation involves the “group-conserved” residues in the class A GPCR family with conservation of up to 99% when considered as a group of small and weakly polar residues (Ala, Gly, Ser, Cys and Thr). These amino acids have been identified in membrane proteins as key determinants in helix-helix interactions [5, 6]. We have previously suggested that helices H1–H4 form a tightly packed core on the basis of the location of the group-conserved positions [7]. The group-conserved residues present on H2, H3 and H4 in β2-AR have both structural and functional roles [8]. The most significant changes in receptor expression and activity were observed upon replacement of the amino acids Ser1614.53 and Ser1654.57 on H4. (The amino acid numbering used in this manuscript incorporates the residue number from the receptor sequence (e.g. Ser165) and a residue number (e.g. 4.57) from a generic numbering system developed by Ballesteros and Weinstein [9].) Substitution at Ser1614.53 and Ser1654.57 by larger residues lowered the expression and activity of the receptor, but did not affect specific binding to the antagonist ligand dihydroalprenolol. Substitution of other group-conserved residues on helices H2–H4 by larger amino acids lowered receptor activity in the order Ala1283.47, Ala762.47, Ser1203.39, and Ala782.49 [8].

The third level of conservation includes those residues that have sequence identities of >90% in the amine subfamily. Each class A GPCR subfamily contains a set of residues that makes it uniquely able to respond to its own ligand. For example, Asp1133.32 on H3 is 92% conserved in the amine subfamily. This residue is the counterion to the positively charged amine [10]. The next highest conservation (92%) is Asn3187.45 on H7. Asn3187.45 corresponds to Ser2987.45 in rhodopsin, a residue that only has 50% conservation in the opsin subfamily. Other residues that are highly conserved within the amine subfamily are Asn692.40 (90%), Trp3137.40 (88%) and Tyr3167.43 (82%).

To fully understand the structure and activation mechanism of any class A GPCR one needs to define the roles of key residues at each level of amino acid conservation. Here, we target two group-conserved residues, Gly3157.42 and Ser3197.46, present on H7. These residues are of particular interest for several reasons. First, they are connected to two different functional microdomains [1113], the conserved aromatic cluster on H6 and the NPxxY motif on H7. Second, they are flanked by residues that have very high sequence conservation in the amine subfamily of receptors: Trp3137.40, Tyr3167.43 and Asn3187.45. Third, while being group-conserved throughout the class A GPCR family, they have very high sequence identity within the amine subfamily (69.2% glycine at position 7.42 and 98% serine at position 7.46). To determine the structural and functional roles of these two group-conserved residues on H7 in the β2-AR, mutants were generated by site-directed mutagenesis and transiently expressed in COS-1 or HEK293S cells, and then ligand binding assays were performed using membrane preparations. To elucidate the effect of these mutations on G-protein signaling, cAMP levels were measured following stimulation by isoproterenol. We discuss the influence of mutation at Gly3157.42 and Ser3197.46 on receptor structure and stability.

2. MATERIALS AND METHODS

2.1. Materials

The β2-AR ligands, alprenolol, isoproterenol, epinephrine and salbutamol were purchased from Sigma (St. Louis, MO, USA). Protease inhibitors and common chemicals were purchased either from Fisher (Ottawa, ON, Canada) or Sigma. The detergent n-dodecyl-β-D-maltoside (DDM) was purchased from Anatrace (Maumee, OH, USA). The monoclonal antibody, rho-1D4, was prepared by the Cell Culture Center (Minneapolis, MN) from a cell line provided by R.S. Molday (University of British Columbia, Vancouver, Canada). Fetal bovine serum was purchased from Sigma and DME High Glucose was from Invitrogen (Burlington, ON, Canada). The β2-AR antagonist [3H] DHA was purchased from GE Healthcare (GE Healthcare Biosciences, Little Chalfont, UK). Synthetic oligonucleotides were purchased from Invitrogen (Carlsbad, CA, USA).

Buffers used were as follows: Phosphate-buffered saline (PBS) buffer: 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4 (pH 7.4); Buffer A (Lysis buffer), 10 mM Tris-HCl, pH 7.4, containing protease inhibitors (1 mM EDTA, 10 µg/ml benzamidine, 10 µg/ml leupeptin, 20 µg/ml soybean trypsin inhibitor, 5 µg/ml aprotinin, and 0.2 mM phenylmethylsulfonyl fluoride); Buffer B (Storage buffer) 50 mM Tris-HCl, pH 7.4, 12.5 mM MgCl2, containing protease inhibitors as in Buffer A; Buffer C (Binding buffer), 75 mM Tris-HCl, pH 7.4, 12.5 mM MgCl2, containing protease inhibitors as in Buffer A. Buffer E (solubilization buffer), 20 mM Tris-HCl (pH 7.4), containing 500 mM NaCl, 10% glycerol, 1% DM and the protease inhibitors as in Buffer A.

2.2. Construction of mutant hamster β2-AR genes

Mutant hamster β2-AR genes in the plasmid expression vector, pMT4, were constructed using the Quick-Change mutagenesis kit (Stratagene, La Jolla, CA, USA). [8]. The DNA sequences of all the mutated genes were verified by automated DNA sequencing (MICB DNA Sequencing Facility, Winnipeg).

2.3. Cell culture and immunoblot analysis

The wild-type β2-AR and mutant genes were expressed in COS-1 cells using a DEAE-dextran based transient transfection method [14, 15]. For transient transfection of HEK293T cells using the plasmid pMT4, lipofectamine 2000 (Invitrogen) mediated transfection was used as described by the manufacturer. Membranes were prepared using Buffers A and B and as described previously [16]. The protein concentration in the resuspended membrane pellet was determined using a modified DC protein assay kit from Bio-Rad Laboratories (Hercules, CA). Approximately 2.5 – 5 µg of the total solubilized membrane protein were resolved by 10% SDS-PAGE and electroblotted onto a nitrocellulose membrane. β2-AR was visualized by immunodetection with the monoclonal antibody, rho-1D4 [16]. The band at approximately 65 kDa corresponds to the completely glycosylated receptor [14].

2.4. Radioligand binding assays

These were carried out in Buffer C, using 2–20 µg of membrane protein and as described earlier [16, 17]. Saturation binding assays were carried out using 0.1 – 20 nM [3H] DHA. Binding of [3H] DHA in the presence of 10 µM alprenolol was used as a measure of nonspecific binding. Specific binding was derived by subtracting nonspecific binding from the total binding and is shown in Figure 7 (supporting information). Competition binding assays were performed using 3 nM [3H] DHA and different concentrations of unlabeled agonists (10−2 –10−9 M) and the reactions kept for 2 hr at room temperature. Radioligand binding data obtained from competition curves were analyzed by non-linear regression analysis to determine the Ki and EC50 values using PRISM software version 4.03 (GraphPad Software Inc, San Diego, CA).

2.5. Immunofluorescence microscopy

HEK293T cells were seeded into six-well tissue culture plates containing sterilized poly-L-lysine (Sigma)-treated glass cover-slips and transiently transfected with wild-type β2-AR or mutant DNA according to the aforementioned transfection protocols. Unless specified, all steps were carried out room temperature. Cells were fixed in 3.7% formaldehyde/1x PBS buffer for 15 min, then permeablized with 0.05% triton X-100/1x PBS buffer for 30 min. The cells were washed and blocked with 1x PBS buffer containing 2% bovine serum albumin (IgG and Protease free) for 1 hr. β2-AR was labeled for 90 min using a 1:1000 dilution of the mouse-anti-rho-1D4 monoclonal antibody (C-terminal tagged β2-AR) and a 1:250 dilution of rabbit-anti-calnexin polyclonal antibody (Abcam, MA, USA; endoplasmic reticulum marker). The labeled receptor was washed and incubated with a fluorescent coupled secondary antibody using a 1:500 dilution of anti-mouse-FITC (Jackson ImmunoResearch labs, PA, USA) and anti-rabbit-Texas Red (Jackson ImmunoResearch Laboratories, PA, USA) for 60 min in the dark. The coverslip was washed twice, mounted with Prolong-antifade-gold (Invitrogen, Molecular probes, CA, USA) for 15 min and its edges sealed with nail-polish. Representative cells were selected and visualized using an Olympus BX61 microscope for cytoplasmic or plasma membrane localization.

2.6. Determination of receptor activation by cAMP assays

Functional characterization of the β2-AR was carried out with HEK293S cells using a commercially available cAMP assay system (DiscoveRx HitHunter ™cAMP XS+, Freemont, CA). HEK293S cells were used as these cells show very small changes in endogenous cAMP upon stimulation with isoproterenol [8, 17]. Measurements of cAMP levels were made according to the directions supplied by the manufacturer. Briefly, 44 hrs after transfection HEK293S cells (100,000 cells/well) were seeded in a 96 well plate and stimulated for 30 minutes with concentrations of agonist (−) isoproterenol ranging from 10−6 M to 10−12 M. Luminescence was read using a Flex Station 3 plate reader (Molecular Devices, CA, USA). The assays were carried out a minimum of three times, each in duplicate and the data were analyzed using PRISM software version 4.03 (GraphPad Software Inc, San Diego, CA). The cAMP values of the mutants expressed as relative luminescence units (RLUs) were normalized to that of wild type β2-AR.

2.7. Occluded surface calculations

The occluded surface (OS) method for the analysis of packing interactions in proteins has been previously described [5, 18]. The method yields packing values of individual amino acids within a protein. Briefly, a packing value is composed of two parameters, the OS area and the distribution of distances to occluded atoms. Using coordinates from a high resolution structure, a molecular dot surface is calculated for each residue using a 1.4-Å probe. The dot density is chosen such that each dot represents 0.215 Å2 of the surface area. A normal is extended radially from each dot until it either intersects the van der Waals surface of a neighboring atom or reaches a length of 2.8 Å (the diameter of a water molecule). The OS is defined as that molecular surface area on the originating atom associated with normals that intersect with another atom surface as opposed to reaching the 2.8-Å limit. All other molecular surface area is considered non-occluded or exposed. The packing value (PV) relates the occluded surface to the total surface of the residue (sum of occluded and non-occluded areas). Division by the total molecular surface area normalizes the packing value to account for various sizes of amino acid residues. Structural waters are not included in the calculations, resulting in surface areas that are non-occluded.

2.8. Homology modeling

The homology model of G315L β2-AR was created in Swiss PDBviewer [19] (http://www.expasy.org/spdbv/) by threading the G315L β2-AR sequence onto the opsin structure (3CAP). The resulting structure was energy minimized in vacuo with the GROMOS96 43B1 parameters set without a reaction field. The energy computations were done with the GROMOS96 implementation of Swiss-PdbViewer.

3. RESULTS

3.1. Influence of mutations on receptor expression and ligand binding

Table 1 presents the saturation binding data of the antagonist DHA for the wild-type β2-AR and the Gly3157.42 and Ser3197.46 mutants. Two types of mutations were made. First, mutations were made to other group-conserved amino acids, for example, glycine to alanine or serine to glycine. The hypothesis is that these conservative substitutions will have a minimal effect on receptor folding and ligand binding. Second, mutations were made to a non-group conserved amino acid with a bulky side chain (i.e. leucine). Total binding, specific binding and non-specific binding of DHA were measured [16]. Specific binding is the difference between the observed total binding and non-specific binding. Binding of [3H] DHA in the presence of 10 µM alprenolol was used as a measure of non-specific binding.

Table I.

Summary of DHA binding to the wild type β2-AR and Gly315 or Ser319 mutant receptors.

The values are expressed as the mean ± S.E (n = 3 to 5 experiments)

Receptor Kd
(nM)
Bmax
(pmol/mg)
Wild type 3.1 ± 0.3 18 ± 0.6
G315A 4.9 ± 0.7 7.8 ± 0.7
G315S 25.3 ± 7.4 5.3 ± 0.1
G315L ND£
S319A 2.8 ± 0.3 48 ± 3.0
S319G 3.0 ± 0.2 42 ± 2.0
S319L 20.6 ± 5.1 9.5 ± 1.5

High non-specific binding (> 20% of total binding)

£

Not detected (no significant specific binding detected under the assay conditions)

When compared to the wild-type β2-AR, the G315A mutant showed a similar affinity for DHA. The G315S mutant exhibited a higher KD and an increased amount of non-specific binding. High non-specific binding can be due to the improperly folded protein interfering with the radioligand assay, or else it can also be due to the mutation perturbing the ligand binding site of the receptor. In contrast to the receptors with these conservative substitutions, the G315L mutant totally failed to bind to DHA in a specific manner.

The binding affinity of DHA to the β2-AR with mutations at the group-conserved site Ser3197.46 was similar to the wild-type receptor for the conservative mutations S319A and S319G, but the KD increased for the non-group conserved leucine substitution, S319L.

The level of receptor expression was quantified by immunoblots and saturation binding assays using DHA (SI Figures 6 and 7). The Bmax is higher than wild-type for the S319A and S319G mutants, and immunoblot analysis showed heterogeneous expression as indicated by the presence of three predominant bands in the molecular mass arrange of 45–kDa, with none of the low expressing mutants producing the ~65 kDa band (SI, Figure 6). Previously, photocrosslinking of β2-AR expressed in COS-1 cells showed that the band at ~65 kDa corresponds to the completely glycosylated receptor [14]. Furthermore, low expressing group-conserved mutants present in H2–H4 also did not show the band at ~65 kDa.

Cell surface expression of the receptor is an excellent indicator of correct protein folding. To elucidate the subcellular localization of the mutant receptors, immunofluorescence microscopy studies on the mutants was carried out in the HEK293T cells (Figure 2). Immunofluorescence microscopy showed that the G315A, S319A and S319G mutants appear to be predominantly localized on the cell surface with only a small amount of receptor present intracellularly, presumably due to receptor that is in-transit (Figure 2). By contrast, a significant amount of the G315S and S319L mutants appear to be retained in the intracellular compartments, while the G315L mutant is predominantly found localized internally in the cytoplasm (Figure 2). Cell surface localization is a strong indicator of correct folding of the G315A, S319A and S319G mutants because misfolded membrane proteins are typically retained either in the Golgi and/or in the endoplasmic reticulum by the endoplasmic reticulum quality control system and targeted for degradation [20].

Figure 2.

Figure 2

Immunofluorescence microscopy showing localization of wild-type β2-AR and the group-conserved mutants expressed in HEK293T cells. Immunofluorescence was performed with the mouse rho-1D4 antibody (A) and the endoplasmic reticulum marker, rabbit anti-calnexin antibody (B). The mouse rho-1D4 antibody was visualized with anti-mouse-FITC secondary antibody (green), and the rabbit anti-calnexin antibody was visualized with anti-rabbit-Texas Red secondary antibody (red). Overlays of (A) and (B) are shown in (C). Yellow arrows show the locations of receptors. In the wild-type, S319A, S319G and G315A mutants, the receptors were predominantly localized at the plasma membrane, whereas in G315S, G315L and S319L the receptors appear to be located in intracellular compartments.

3.2. Agonist competition assays and Gαs mediated signaling

Table II presents the binding of unlabelled agonists to the wild type β2-AR and mutant receptors as determined by competition with 3 nM [3H] DHA. We characterized the ligand binding properties of the wild-type β2-AR and the G315A, S319A and S319G β2-AR mutants with the following β2-AR agonists: (−) isoproterenol (full agonist), epinephrine (natural, full agonist) and salbutamol (partial agonist). We could not determine the binding properties of the G315S, G315L and S319L mutants as these mutants showed high non-specific binding under our assay conditions. Since the affinity of DHA to the wild-type receptor is similar for the G315A, S319A and S319G mutants (see Table I), we can estimate the binding affinities of the various agonists from the competition data in Table 2. Salbutamol has a lower affinity to the wild-type receptor than either epinephrine or isoproterenol; i.e. the concentration needed to displace DHA is 5–6 times greater for salbutamol. The S319A and S319G mutants showed slight decreases in affinity for all three agonists. The G315A substitution had the most marked effect in the competition assay, requiring a 200-fold increase in agonist concentration to displace the DHA antagonist (Table II).

Table II.

Summary of competition ligand binding of wild type β2-AR and mutant receptors.

Receptor Ligands (Ki)
µM (95% confidence intervals)

Epinephrine (−) Isoproterenol Salbutamol
Wild type 4.9 (3.5 – 7.0) 4.2 (2.4 – 7.5) 25 (21 – 30)
G315A 1014 (372 – 2760) 658 (304 – 1237) 1616 (398 – 5680)
S319A 127 (65 – 246) 31 (17 – 56) 204 (85 – 488)
S319G 141 (68 – 293) 64 (30 – 135) 154 (60 – 394)

Data obtained from determinations of two or more independent transfections and analyzed by non-linear regression as described under methods. The 95% confidence intervals for each measurement are indicated in parenthesis. The binding of unlabeled agonists to β2-AR was determined by competition with the antagonist 3 nM [3H] DHA as the radioligand.

The agonist competition data for S319A and S319G are in agreement with the agonist activation of the wild-type and mutant receptors measured by cAMP assays (Figure 3). For the measurements on the Gly315 mutants treated with isoproterenol in a dose-dependent manner, the relative activity decreased in the order G315A > G315S > G315L. For the Ser319 mutants, the relative activity decreased in the order S319A > S319G > S319L. In general, the basal activity of the mutant receptors was higher than that of the wild-type β2-AR (indicated by arrows in Figure 3). The mutants showed agonist independent or constitutive activity to various degrees, for the S319A and S319G it was 15–20% of wild type, while for the G315A and G315S it was 10–15% of wild type. An unexpected finding was the G315A mutant exhibited high agonist dependent cAMP production even though it had the lowest affinity for (−) isoproterenol of the mutants assayed in Table II.

Figure 3.

Figure 3

Characterization of Gαs-mediated signaling of the wild-type and group-conserved helix H7 mutants of β2-AR. Receptor activity was determined by measuring cAMP production using transiently transfected HEK293S cells. Shown are the basal (zero concentration) and agonist (isoproterenol) induced cAMP production of the wild-type receptor and the Gly315 and Ser319 mutants. Arrows indicate an increase in the basal activity of the mutants over the wild type receptor. The results are expressed as a percentage of the wild type β2-AR activity, and are from at least three independent experiments performed in duplicate.

3.3. Molecular packing of Gly3157.42

The crystal structure of β2-AR show Gly3157.42 is tightly packed against Cys2856.47 and Trp2866.48 on H6 [2] (Figure 4A). The packing interaction can be assessed by the method of occluded surfaces [5, 18]. Occluded surface calculations show that the packing value for Gly3157.42 is high (0.65) indicating that the small glycine side chain does not form a water binding site in β2-AR. For comparison, the average packing value for amino acids in helices of membrane proteins is 0.44 [5]. In helical membrane proteins, glycine has the highest amino acid packing value (0.52), followed by proline (0.51) and alanine (0.49) [5].

Figure 4.

Figure 4

Molecular packing of Gly3157.42 and Leu3157.42 in β2-AR. (A) Crystal structure of β2-AR (2RH1) showing van der Waals interaction of Trp2866.48 and Gly3157.42. (B) Homology model of G315L β2-AR where the G315L β2-AR sequence was threaded onto the structure of active opsin (3CAP) and the resulting structure was energy minimized with 1000 steps steepest descent. The inactive structure of rhodopsin (C) and the active structure of opsin (D) are shown for comparison.

The replacement of Gly3157.42 with amino acids having larger side chains results in a steric clash with the side chain of Trp2866.48 (packing value 0.56 [5]). Since the glycine side chain is part of the helix backbone, larger amino acids at position 7.42 can be accommodated by rotation of the Trp2866.48 side chain, which may be coupled to the rotation of transmembrane helix H6 (24). Figure 4B shows a model of the G315Lβ2-AR structure based on homology with the structure of active opsin. The leucine side chain at position 315 is well packed against Trp2866.48. For comparison, Figures 4C and D show the structures of inactive rhodopsin and active opsin. In the transition from rhodopsin to opsin, Trp265 moves away from Ala295, whose packing value decreases from 0.55 to 0.44. Displacement of the highly conserved Trp2866.48 and rotation of H6 would explain the constitutive activity observed for the Gly3157.42 mutants.

3.4. Molecular packing of Ser3197.46

Occluded surface calculations yield a smaller packing value (0.51) for Ser3197.46 than for Gly3157.42. Nevertheless, the packing value is higher than the average packing value for serine in membrane proteins (0.47) [5] and reflects the tightly hydrogen bonded network surrounding the Ser3197.46 side chain (Figure 5). The side chain of Ser3197.46 forms hydrogen bonds with Asp792.50 (3.3 Å) and Tyr3167.43 (3.1 Å). In addition, Ser3197.46 hydrogen bonds with water 534 (3.1 Å), a structural water that also coordinates Asp792.50, Trp2866.48, and Gly3157.42 (Figure 5B). Replacement of Ser3197.46 with non-polar residues (S319A, S319G, S319L) results in loss of its hydrogen bonding interactions.

Figure 5.

Figure 5

Crystal structure of the β2-AR in the region of Gly3157.42 and Ser3197.46. (A) Packing of Gly3157.42 with Trp2866.48. An increase in size of the amino acid at position 7.42 causes a steric clash with Trp2866.48 on H6 and is predicted to displace the Trp2866.48 side chain toward the extracellular surface. (B) Hydrogen bonding interactions of Ser3197.46. The side chain hydroxyl group of Ser3197.46 side chain is hydrogen bonded to the carboxyl C(O)OH of Asp792.50 (3.3 Å), to the backbone carbonyl of Tyr3167.43 (3.1 Å) and to water 534 (3.1 Å), while the backbone carbonyl of Ser3197.46 makes contact with the side chain NH of Asn511.50 (3.1 Å). Water 534 is shown hydrogen bonded to the backbone of Gly3157.42. (C) Hydrogen bonding network connecting the indole NH of Trp2866.48 to the amide side chain of Asn3227.49. Water 534 in β2-AR mediates hydrogen bonding between the Trp2866.48 indole NH (3.48 Å), Ser3197.46 CβOH (2.82 Å), Asn3187.45 NH2 (3.11 Å) and Gly3157.42 (C=O) (3.38 Å). Water 534 is also hydrogen bonded to Wat548, which in turn is hydrogen bonded to Asn322 through Wat532. The same overall set of interactions appears to exist in the recent crystal structure of the CXCR4 receptor where cysteine occurs at position 7.46 and histidine occurs at position 7.45 [24]. The polar imidizole of histidine is located between the conserved indole ring of Trp6.48 and Cys7.46.

4. DISCUSSION

We targeted Gly3157.42 and Ser3197.46 because of their position between two key functional microdomains in β2-AR. Gly3157.42 is in contact with Cys2856.47 and Trp2866.48 of the conserved CWxP motif on H6. Ser3197.46 hydrogen bonds directly with the conserved Asn511.50 on H1 and Asp792.50 on H2, and bridges Trp2866.48 and Asn3227.49 of the conserved NPxxY motif on H7 through water mediated hydrogen bonds. Gly3157.42 and Ser3197.46 are also flanked by amino acids that have high sequence conservation within the amine subfamily of receptors (Trp3137.40, Tyr3167.43 and Asn3187.45). As a result, these two group conserved amino acids are strategically positioned between the ligand-binding site on the extracellular side of the receptor and the ionic lock on the cytoplasmic side of the receptor.

4.1. Gly3157.42 functions as a molecular notch to stabilize Trp2866.48 in an inactive position

Figure 5A shows the close packing interaction of Gly3157.42 with the indole ring of Trp2866.48. These residues are 69% and 96% conserved in the amine receptor subfamily, respectively. We found that the conservative mutation of Gly3157.42 to alanine exhibits agonist-independent cAMP production. The constitutive activity suggests that Gly3157.42 is stabilizing Trp2866.48 in an inactive conformation. This packing arrangement is similar to the packing of Ala2957.42 against Trp2656.48 in rhodopsin [21, 22] where substitution of Ala2957.42 with valine results in constitutive activity and leads to autosomal dominant congenital stationary night blindness [23]. A similarly close packing interaction between Ala2917.42 and Trp2526.48 is observed in the recent structure of the CXCR4 receptor, a member of the large subfamily of GPCRs that bind peptide ligands [24].

Trp2866.48 has been proposed to be part of the rotamer toggle switch involved in receptor activation [25], although the recent crystal structure of active opsin shows only a displacement of Trp2656.48 rather than a change in the side chain rotamer angle (see Figure 4D). Evidence for displacement of the Trp2656.48 side chain in activated rhodopsin comes from NMR measurements showing the gain of a direct packing interaction between the retinal C19 methyl group and the Trp2656.48 side chain, in concert with a loss of packing interactions with the retinal C18 and C20 methyl groups [21, 26]. Substitution of larger residues at position 7.42 in the β2-AR would be expect to displace the conserved tryptophan as suggested by computational studies of activated β2-AR [27].

Gly3157.42 is also in close contact with Cys2856.47. Cysteine is highly conserved at position 6.47; mutation to serine in the β2-AR shows normal ligand binding, but reduced activity [25, 28], while mutation to threonine results in constitutive activity [25]. The mechanism of receptor activation in the C285T mutant may involve a steric clash of the β-branched threonine methyl group with Gly3157.42 rather than a change in rotamer angle since the predominant conformer for threonine in α-helices is gauche+ [25], which is the observed conformer for Cys2856.47 in the carazolol-bound structure of β2-AR. Moreover, the Cys2856.47 side chain is more exposed to cysteine reactive reagents in a constitutively active mutant of β2-AR [29] and upon agonist binding [30]. Together with our mutational results on Gly3157.42, these cysteine accessibility studies are consistent with a more open structure in the active receptor being due to displacement of Trp2866.48 from a molecular notch formed by Gly3157.42.

4.2. Ser3197.46 mediates hydrogen bonding interactions between Trp2866.48 and Asn3227.49

Ser3197.46 is highly conserved (98%) in the amine subfamily and is in a key position between Asn511.50, Asp792.50, Trp2866.48, and Asn3227.49. These residues are all highly conserved across the class A GPCRs.

Both the backbone carbonyl and side chain hydroxyl groups of Ser3197.46 form hydrogen bonds that have structural and functional importance. The Ser3197.46 carbonyl does not form an intra-helical hydrogen bond due to its position one helix turn above Pro3237.50 of the conserved NPxxY sequence. The backbone carbonyl of Ser3197.46 forms an inter-helical hydrogen bond with the amide NH2 functional group of Asn511.50, the most highly conserved residue in the class A GPCRs. Along with the backbone carbonyl at position 1.46, another group-conserved residue, this hydrogen bond functions to orient the conserved Asn511.50 side chain (Figure 5B) [31].

The Ser3197.46 side chain is in the center of a hydrogen-bonding network connecting Trp2866.48 to Asn3227.49. Asn3227.49 is part of the conserved NPxxY motif on H7 that is involved in receptor activation. We found that the conservative mutation of Ser3197.46 to alanine results in constitutive activity. Unlike the Gly3157.42 to alanine mutation in β2-AR and the Ala2957.42 to valine mutation in rhodopsin that lead to constitutive activity, the S319A mutation does not increase the molecular volume of the group-conserved side chain, but rather removes its ability to hydrogen bond. Ser3197.46 is hydrogen bonded to water 534, a conserved structural water within the transmembrane core of the receptor. In rhodopsin, water 2015 mediates interaction of Trp2656.48, Ser2987.45 and Tyr3017.48. In both β2-AR and rhodopsin, this conserved water is hydrogen bonded to several additional conserved water molecules that form a shell surrounding the side chain of Asn7.49. While the details of the structural changes between Trp6.48 and Asn7.49 have not been determined by crystallography or NMR spectroscopy in either the β2-AR or rhodopsin, NMR measurements of rhodopsin show that displacement of Trp2656.48 upon activation weakens the water-mediated hydrogen bond between the Trp2656.48 indole NH and Asn3027.49 amide side chain [21]. As a result, motion of Trp2866.48 away from Gly3157.42 in the β2-AR upon agonist binding would be expected to alter the hydrogen bonding network illustrated in Figure 5C.

The idea that conserved structural waters can act as allosteric regulators of GPCR function was introduced by Palczewski and colleagues [32]. These authors showed that the interior water molecules do not exchange with bulk solvent suggesting that structural waters represent an intrinsic part of the interfaces between helices H1, H2, H6 and H7. We propose that the structural waters in combination with the group-conserved residues on these helices (see Figure 5A) create an interface that facilitates the rotation of H6 relative to H7 during activation.

4.3. Interplay between the three levels of amino acid conservation in class A GPCRs

Figure 5 presents the core conserved transmembrane region of the β2-AR to illustrate the interplay between the signature, group-conserved and subfamily specific amino acids. Trp2866.48 is sandwiched between Gly3157.42 and Val1173.36. The residue at position 3.36 on H3 appears to play a role that parallels that of group-conserved residue 7.42 on H7. In rhodopsin, residue 3.36 is a glycine, which has very high conservation (95%) in the rhodopsin subfamily of receptors. Replacement of this glycine with larger residues results in dark activity of rhodopsin, where the activity is linearly correlated with the residue volume [33]. In a similar fashion, mutation of the residue at position 3.36 in receptors of the amine subfamily has been shown to modulate the receptor activity. The specific residue at this position in the 5HT4 and histamine H1 receptors has been associated with constitutive (basal) activity, and mutation can either increase or decrease this activity. For example, in the histamine H1 receptor substitution of the wild-type serine with cysteine or threonine increases activity, while substitution with alanine decreases activity [34]. Pardo and co-workers proposed that when Trp6.48 rotates upon ligand binding, Ser3.36 forms an interhelical hydrogen bond with Asn7.45 on H7 [34]. Asn7.45 has the second highest level of subfamily conservation in the amine receptors (92%). Threonine at position 3.36 has the highest constitutive activity and may be correlated with a preference for the g+ rotamer. In the 5HT4 receptor, the wild-type residue is threonine and substitution with alanine or serine decreases activity [35]. The role of the residue at position 3.36 extends beyond the amine and rhodopsin subfamilies to other class A GPCRs. Schwartz and colleagues concluded residue 3.36 often influences the function of the Trp6.48 rotamer toggle switch, but that it acts in a highly context-dependent manner [27]. In the gherlin peptide hormone receptor, mutation of the wild-type threonine residue at 3.36 to alanine was found to increase, rather than decrease, receptor activity [36]. Together, these results illustrate the interplay between the three levels of class A receptor conservation: signature conserved (Trp6.48, Asp2.50, Asn7.49), group-conserved (Cys647, Gly/Ala7.42, Ser/Ala7.46), subfamily conserved (Gly/Ser/Thr/Val3.36 and Asn7.45).

5. CONCLUSION

We show that the two group-conserved amino acid residues, Gly3157.42 and Ser3197.46 play important structural and functional roles in the β2-AR. Gly3157.42 stabilizes Trp2866.48 in the inactive conformation, while Ser3197.46 is in the center of a hydrogen bonding network that stretches from Trp2866.48 to Asn3227.49. The hydrogen-bonding interactions between Trp2866.48 and Asn3227.49 appear to be strongly coupled. The conservative mutation to alanine of either Gly3157.42 or Ser3197.46 results in an increase in the basal activity of the receptor. We propose that the group-conserved residues on H7 along with conserved structural waters create an extended interface between the transmembrane helices that facilitates the motion of H6 relative to H7 upon receptor activation. These changes would be encompassed within the global toggle switch mechanism proposed by Schwartz and colleagues [37].

Supplementary Material

01
02

ACKNOWLEDGEMENTS

We thank Ms. Thi Le for technical assistance. This work was supported by grants from Canadian Institute of Health Research (ROP 92389), and Manitoba Health Research Council (MHRC) to PC and from the NIH to S.O.S (RO1-GM-41412). PC holds a New Investigator Salary Award from the Heart and Stroke Foundation of Canada (HSFC).

List of nonstandard abbreviations

β2-AR

β2-adrenoreceptor

Bmax

Binding maximum of the ligand for the receptor

COS-1

Monkey kidney cells

GPCRs

G protein-coupled receptors

HEK293

human embryonic kidney cells

[3H] DHA

tritium labeled dihydroalprenolol

Kd

equilibrium dissociation constant of the ligand

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Electronic supplementary material.

Electronic supplementary material contains Figures 6 and 7. Figure 6 shows the immunoblot analysis of β2-AR and mutants using the monoclonal antibody rho-1D4. Immunoblotting was carried out as described in the materials and methods. The arrow indicates the position of the fully glycosylated receptor. Figure 7 shows the saturation binding assays for membrane bound β2-AR and mutants from COS-1 cells using the radioligand [3H] DHA. Saturation binding assays were performed as described in the materials and methods.

References

  • 1.Dixon RAF, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, Bolanowski MA, Bennett CD, Rands E, Diehl RE, Mumford RA, Slater EE, Sigal IS, Caron MG, Lefkowitz RJ, Strader CD. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin. Nature. 1986;321:75–79. doi: 10.1038/321075a0. [DOI] [PubMed] [Google Scholar]
  • 2.Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science. 2007;318:1258–1265. doi: 10.1126/science.1150577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Li J, Edwards PC, Burghammer M, Villa C, Schertler GFX. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 2004;343:1409–1438. doi: 10.1016/j.jmb.2004.08.090. [DOI] [PubMed] [Google Scholar]
  • 4.Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289:739–745. doi: 10.1126/science.289.5480.739. [DOI] [PubMed] [Google Scholar]
  • 5.Eilers M, Patel AB, Liu W, Smith SO. Comparison of helix interactions in membrane and soluble α-bundle proteins. Biophys. J. 2002;82:2720–2736. doi: 10.1016/S0006-3495(02)75613-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Eilers M, Shekar SC, Shieh T, Smith SO, Fleming PJ. Internal packing of helical membrane proteins. Proc. Natl. Acad. Sci. U.S.A. 2000;97:5796–5801. doi: 10.1073/pnas.97.11.5796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Liu W, Eilers M, Patel AB, Smith SO. Helix packing moments reveal diversity and conservation in membrane protein structure. J. Mol. Biol. 2004;337:713–729. doi: 10.1016/j.jmb.2004.02.001. [DOI] [PubMed] [Google Scholar]
  • 8.Chelikani P, Hornak V, Eilers M, Reeves PJ, Smith SO, RajBhandary UL, Khorana HG. Role of group-conserved residues in the helical core of β2-adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A. 2007;104:7027–7032. doi: 10.1073/pnas.0702024104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ballesteros JA, Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 1995;25:366–428. [Google Scholar]
  • 10.Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, Dixon RAF. Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 1988;263:10267–10271. [PubMed] [Google Scholar]
  • 11.Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, Konvicka K, Chi L, Millar RP, Davidson JS, Weinstein H, Sealfon SC. Functional microdomains in G-protein-coupled receptors - the conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J. Biol. Chem. 1998;273:10445–10453. doi: 10.1074/jbc.273.17.10445. [DOI] [PubMed] [Google Scholar]
  • 12.Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001;60:1–19. [PubMed] [Google Scholar]
  • 13.Visiers I, Ebersole BJ, Dracheva S, Ballesteros J, Sealfon SC, Weinstein H. Structural motifs as functional microdomains in G-protein- coupled receptors: Energetic considerations in the mechanism of activation of the serotonin 5-HT2A receptor by disruption of the ionic lock of the arginine cage. Int. J. Quantum Chem. 2002;88:65–75. [Google Scholar]
  • 14.Noda K, Saad Y, Graham RM, Karnik SS. The high-affinity state of the β2-adrenergic receptor requires unique interaction between conserved and nonconserved extracellular loop cysteines. J. Biol. Chem. 1994;269:6743–6752. [PubMed] [Google Scholar]
  • 15.Oprian DD, Molday RS, Kaufman RJ, Khorana HG. Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Proc. Natl. Acad. Sci. U.S.A. 1987;84:8874–8878. doi: 10.1073/pnas.84.24.8874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chelikani P, Reeves PJ, Rajbhandary UL, Khorana HG. The synthesis and high-level expression of a β2-adrenergic receptor gene in a tetracycline-inducible stable mammalian cell line. Protein Sci. 2006;15:1433–1440. doi: 10.1110/ps.062080006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Arakawa M, Yanamala N, Upadhyaya J, Halayko A, Klein-Seetharaman J, Chelikani P. The importance of valine 114 in ligand binding in β2-adrenergic receptor. Protein Sci. 2010;19:85–93. doi: 10.1002/pro.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pattabiraman N, Ward KB, Fleming PJ. Occluded molecular surface: analysis of protein packing. J. Mol. Recognit. 1995;8:334–344. doi: 10.1002/jmr.300080603. [DOI] [PubMed] [Google Scholar]
  • 19.Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis. 1997;18:2714–2723. doi: 10.1002/elps.1150181505. [DOI] [PubMed] [Google Scholar]
  • 20.Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 2003;4:181–191. doi: 10.1038/nrm1052. [DOI] [PubMed] [Google Scholar]
  • 21.Crocker E, Eilers M, Ahuja S, Hornak V, Hirshfeld A, Sheves M, Smith SO. Location of Trp265 in metarhodopsin II: Implications for the activation mechanism of the visual receptor rhodopsin. J. Mol. Biol. 2006;357:163–172. doi: 10.1016/j.jmb.2005.12.046. [DOI] [PubMed] [Google Scholar]
  • 22.Gouldson PR, Kidley NJ, Bywater RP, Psaroudakis G, Brooks HD, Diaz C, Shire D, Reynolds CA. Toward the active conformations of rhodopsin and the β2-adrenergic receptor. Proteins. 2004;56:67–84. doi: 10.1002/prot.20108. [DOI] [PubMed] [Google Scholar]
  • 23.Zeitz C, Gross AK, Leifert D, Kloeckener-Gruissem B, McAlear SD, Lemke J, Neidhardt J, Berger W. Identification and functional characterization of a novel rhodopsin mutation associated with autosomal dominant CSNB. Investigative Ophthalmology & Visual Science. 2008;49:4105–4114. doi: 10.1167/iovs.08-1717. [DOI] [PubMed] [Google Scholar]
  • 24.Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330:1066–1071. doi: 10.1126/science.1194396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. β2 adrenergic receptor activation - Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 2002;277:40989–40996. doi: 10.1074/jbc.M206801200. [DOI] [PubMed] [Google Scholar]
  • 26.Ahuja S, Crocker E, Eilers M, Hornak V, Hirshfeld A, Ziliox M, Syrett N, Reeves PJ, Khorana HG, Sheves M, Smith SO. Location of the retinal chromophore in the activated state of rhodopsin. J. Biol. Chem. 2009;284:10190–10201. doi: 10.1074/jbc.M805725200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Holst B, Nygaard R, Valentin-Hansen L, Bach A, Engelstoft MS, Petersen PS, Frimurer TM, Schwartz TW. A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors. J. Biol. Chem. 2010;285:3973–3985. doi: 10.1074/jbc.M109.064725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Fraser CM. Site-directed mutagenesis of β-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation. J. Biol. Chem. 1989;264:9266–9270. [PubMed] [Google Scholar]
  • 29.Javitch JA, Fu DY, Liapakis G, Chen JY. Constitutive activation of the β2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem. 1997;272:18546–18549. doi: 10.1074/jbc.272.30.18546. [DOI] [PubMed] [Google Scholar]
  • 30.Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor. EMBO J. 1997;16:6737–6747. doi: 10.1093/emboj/16.22.6737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Smith SO. Structure and activation of the visual pigment rhodopsin. Annu. Rev. Biophys. 2010;39:309–328. doi: 10.1146/annurev-biophys-101209-104901. [DOI] [PubMed] [Google Scholar]
  • 32.Angel TE, Gupta S, Jastrzebska B, Palczewski K, Chance MR. Structural waters define a functional channel mediating activation of the GPCR, rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 2009;106:14367–14372. doi: 10.1073/pnas.0901074106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Han M, Lin SW, Smith SO, Sakmar TP. The effects of amino acid replacements of glycine 121 on transmembrane helix 3 of rhodopsin. J. Biol. Chem. 1996;271:32330–32336. doi: 10.1074/jbc.271.50.32330. [DOI] [PubMed] [Google Scholar]
  • 34.Jongejan A, Bruysters M, Ballesteros JA, Haaksma E, Bakker RA, Pardo L, Leurs R. Linking agonist binding to histamine H-1 receptor activation. Nat. Chem. Biol. 2005;1:98–103. doi: 10.1038/nchembio714. [DOI] [PubMed] [Google Scholar]
  • 35.Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, Pillot M, Dumuis A, Claeysen S, Bockaert J, Pardo L. Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol. Pharmacol. 2009;75:982–990. doi: 10.1124/mol.108.053686. [DOI] [PubMed] [Google Scholar]
  • 36.Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, Schwartz TW. Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol. Pharmacol. 2009;75:44–59. doi: 10.1124/mol.108.049189. [DOI] [PubMed] [Google Scholar]
  • 37.Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE. Molecular mechanism of 7TM receptor activation - A global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 2006;46:481–519. doi: 10.1146/annurev.pharmtox.46.120604.141218. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

01
02

RESOURCES